Aerovate Therapeutics和私人控股的Jade Biosciences已达成一项强制性合并协议，进行全股票交易，由此产生的实体将专注于推进Jade的生物制品组合，包括JADE-001 For Iga肾病

2024-10-31 19:23

Merger to create a company focused on advancing Jade Biosciences' portfolio of novel therapies that aim to redefine the standard of care for patients with autoimmune diseases
Jade Biosciences, the fourth company founded on assets licensed from Paragon Therapeutics, expects to initiate a clinical trial for JADE-001 in the second half of 2025
Approximately $300 million raised to date, including anticipated proceeds from an oversubscribed pre-closing private financing, expected to fund operations through 2027
Upon completion of the merger, the combined company plans to operate under the name Jade Biosciences and trade on Nasdaq under the ticker symbol "JBIO."